Roche Posts Strong Growth In Emerging Markets In First Nine Months

BMI View: Although developed states will continue to be core revenue streams for major pharmaceutical companies, the negative impact of healthcare reforms and the introduction of government price erosion mechanisms will continue to negatively impact sales growth in these regions. Therefore, BMI believes the importance of the BRIC markets - and other leading emerging markets including Mexico, Turkey and South Korea - to ensuring revenue growth will

To read the full article, please choose one of the following options: